John Inge Johnsen

John Inge Johnsen

Principal Researcher | Docent
Visiting address: Widerströmska huset, hiss 1, plan 8 Tomtebodavägen 18A, 17177 Stockholm
Postal address: K6 Kvinnors och barns hälsa, K6 Barnonkologi och Barnkirurgi Kogner/Johnsen, 171 77 Stockholm

About me

  • Dr. John Inge Johnsen received his PhD diploma at University of Tromsö,
    Norway under the supervision of Professor Terje Traavik in 1994. His thesis
    focused on the characterization of regulatory genetic elements in
    polyomaviruses and the effects these regulatory regions have on host/virus
    After finishing his PhD, Dr. Johnsen went on to pursue his main scientific
  • cancer biology, oncogenes and tumor suppressor genes and 1995 he
    joined Professor Eric Stanbridge´s research group at University of
    California, Irvine where he studied the effects of p53 and genes regulated by
    p53 on cancer development.
    After spending two years at the University of Tromsö as an assistant
    professor/lecturer Dr. Johnsen joined professor Per Kogner´s research group
    at Karolinska Institutet as a postdoctoral fellow where he together with Dr.
    Kogner built up the childhood neural tumor research consortium.
    Dr. Johnsen became Associate professor at Karolinska Instituet in 2010.
    1984-1990 Msc, University of Tromsö, Norway
    1991-1994 PhD, University of Tromsö, Norway
    1995-1997 Postdoc, Dr.Stanbridge´s lab, University of California, Irvine,
    1997-1998 Postdoc, Dept. of Pediatrics, University of Tromsö Norway
    2001-2003 Postdoc, Childhood Cancer Research Unit, Karolinska Istitutet


  • The main focus of our research group is to search for new treatment options
    that lead to better survival, less treatment-related complications and better
    quality of life for children with medulloblastoma and neuroblastoma. This is
    done by applying different Omic techniques to characterize the molecular
    landscape of malignant and corresponding non-cancerous cells within the tumor
    microenvironment and to use a translational approach applying preclinical in
    vivo models to characterize the anti-tumorigenic effects of drugs and
    compounds targeting specific biological aberrations in cancer cells or
    populations of cells located within the tumor microenvironment.


All other publications



  • Principal Researcher, Department of Women's and Children's Health, Karolinska Institutet, 2022-

Degrees and Education

  • Docent, Karolinska Institutet, 2010

News from KI

Events from KI